Fig 1.
Modulation of CRP relative to pre-treatment is associated with overall response post atezolizumab treatment but not with docetaxel treatment in the POPLAR and OAK studies.
A. POPLAR Studies B. OAK Studies. Trend plots of CRP change from baselines of patients in different response categories in both the POPLAR and OAK study using simple means for each visit separately. Shaded regions indicate point-wise 95% confidence intervals. n: number of patients with a change from baseline value at a particular visit, excluding patients with missing or not evaluable best confirmed overall response. N: number of patients at baseline in each best confirmed overall response category.
Fig 2.
CRP ratios relative to pre-treatment is associated with overall response post-atezolizumab treatment but not with docetaxel treatment in the POPLAR and OAK studies.
CRP log 2 ratio relative to pre-treatment or C1D1 pre-dose for each patient for each treatment arm for the first four visits with dotted lines marking an increase (1.5 fold increase) or decreased (1.5 fold decrease) relative to pre-treatment. CR, complete response; CRP, c-reactive protein; PD, disease progression; PR, partial response; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SD, stable disease.
Table 1.
PFS and OS benefit based on CRP changes at 6 weeks in OAK.
Table 2.
Patient demographics and clinical characteristics in the three CRP fold change buckets for atezolizumab in OAK.
Table 3.
Patient demographics and clinical characteristics in the three CRP fold change buckets for docetaxel in OAK.
Fig 3.
Landmark OS and PFS Kaplan-Meier curves for patients binned by CRP changes at 6 weeks.
Landmark OS and PFS Kaplan-Meier curves were plotted based on patients binned by CRP fold changes at 6 weeks. (3a) PFS (Top) and (3b) OS (Bottom) were calculated from 6 weeks or cycle 3 day 1 (C3D1) post-treatment; patients censored or with an event before this time were excluded from this analysis. Patients treated with atezolizumab are in the solid lines and patients treated with docetaxel are in the broken lines. The first panel is patients who had CRP decrease (blue), the middle panel is patients who showed no change in CRP (black) and the last panel is patients who showed an increase in CRP (red). CRP, C-reactive protein; HR, hazard ratio; OS, overall survival; PFS, progression free survival.
Table 4.
OS benefit based on ORR using RECIST 1.1 scans and CRP changes at 6 weeks in OAK.